Drug Profile

CG-SpikeDown - Caregen

Alternative Names: CG-SpikeDown

Latest Information Update: 28 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Caregen
Class Antivirals; Peptides
Mechanism of Action Angiotensin-converting enzyme 2 expression inhibitors; Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Mar 2026 No recent reports of development identified for preclinical development in COVID-2019-infections in South Korea (Intranasal)
16 Mar 2022 Caregen announces intention to submit IND application for phase I/IIa trials to US FDA for Covid-2019 infections (Caragen pipeline, March 2022)
16 Mar 2022 Pharmacodynamics data from the in vivo studies in Covid-2019 inefctions released by Caragen (Caragen pipeline, March 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com